Proteome Sciences Statement re Share Price Movement

Statement re Share Price Movement

5th February 2008

The Board of Proteome Sciences has noted the recent movement in the Company’s share price and that they are not aware of any reason for the share price increase.

In the trading update released on 21 December 2007, the Board reported that it continued to view future prospects for TMT® commercialisation with increasing confidence, with the related licence negotiations expected to be concluded in early 2008. This remains the case and the Company will issue a further update on licence negotiations in due course.

Suggested Articles

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.

The series B positions ex-AveXis executives to build a biotech with a broad gene therapy pipeline and infrastructure to match.

A variant of the ACE2 receptor could work as a COVID-19 therapeutic by drawing the virus away from healthy cells, scientists reported.